ImmunoPrecise Antibodies Ltd. (IPA)

ImmunoPrecise Antibodies Balance Sheet

Financials in millions CAD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 31, 2024	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021	Apr 30, 2020
Cash & Equivalents	3.91	3.46	8.28	29.97	41.76	2.61
Cash & Short-Term Investments	3.91	3.46	8.28	29.97	41.76	2.61
Cash Growth	-41.85%	-58.22%	-72.37%	-28.24%	1502.42%	-52.37%
Accounts Receivable	3.19	4.07	3.88	3.13	3.63	3.66
Other Receivables	0.32	0.41	0.54	0.28	0.49	0.09
Receivables	3.52	4.48	4.42	3.41	4.12	3.75
Inventory	1.87	2.14	2.06	1.62	1.2	0.82
Prepaid Expenses	1.72	1.41	2.04	2.48	1.78	0.53
Total Current Assets	11.02	11.49	16.79	37.47	48.86	7.7
Property, Plant & Equipment	16.44	16.7	10.39	3.56	4.02	3.06
Long-Term Investments	-	-	0.12	0.14	0.11	0.12
Goodwill	7.85	7.69	19.17	19.64	7.78	7.91
Other Intangible Assets	23.42	23.56	30.91	32.37	6.03	8.19
Long-Term Deferred Charges	-	-	0.02	0.03	0.03	0.12
Other Long-Term Assets	0.57	0.56	0.42	0.45	0.13	0.17
Total Assets	59.3	59.99	77.81	93.65	66.96	27.26
Accounts Payable	4.52	4.07	2.49	4.37	1.81	1.35
Accrued Expenses	0.3	0.85	0.9	0.43	1.34	0.41
Current Portion of Long-Term Debt	-	-	-	1.31	-	2.12
Current Portion of Leases	1.61	1.56	1.12	0.99	0.99	0.75
Current Income Taxes Payable	0.56	-	-	0.42	0.33	-
Current Unearned Revenue	1.3	1.35	0.98	1.03	1.11	1.48
Other Current Liabilities	0.29	0.28	0.44	0.74	0.5	1.82
Total Current Liabilities	11.17	8.12	5.92	9.29	6.07	7.93
Long-Term Debt	-	-	-	-	1.53	0.5
Long-Term Leases	11.9	12.12	6.15	0.47	0.94	1.13
Long-Term Deferred Tax Liabilities	3.38	5.83	7.66	8.11	1.49	1.6
Other Long-Term Liabilities	-	-	0.28	0.5	-	1.01
Total Liabilities	26.45	26.07	20.01	18.36	10.04	12.18
Common Stock	120.26	119.77	117.47	114.56	80.1	34.09
Additional Paid-In Capital	12.55	12.39	10.8	9.63	7.2	3.78
Retained Earnings	-102.56	-100.27	-73.09	-46.53	-29.82	-22.48
Comprehensive Income & Other	2.6	2.03	2.63	-2.38	-0.56	-0.3
Total Common Equity	32.85	33.92	57.8	75.29	56.92	15.09
Shareholders' Equity	32.85	33.92	57.8	75.29	56.92	15.09
Total Liabilities & Equity	59.3	59.99	77.81	93.65	66.96	27.26
Total Debt	16.1	13.68	7.27	2.77	3.46	4.51
Net Cash (Debt)	-12.19	-10.22	1.01	27.2	38.3	-1.9
Net Cash Growth	-	-	-96.28%	-28.99%	-	-
Net Cash Per Share	-0.47	-0.40	0.04	1.38	2.32	-0.14
Filing Date Shares Outstanding	27.92	27.3	24.94	24.84	19.23	18.72
Total Common Shares Outstanding	27.3	26.94	25.05	24.48	19.17	13.98
Working Capital	-0.15	3.36	10.87	28.18	42.79	-0.23
Book Value Per Share	1.20	1.26	2.31	3.07	2.96	1.08
Tangible Book Value	1.58	2.68	7.73	23.29	43.11	-1.01
Tangible Book Value Per Share	0.06	0.10	0.31	0.95	2.24	-0.07
Buildings	-	-	-	-	-	2.38
Machinery	5.52	5.39	6.81	5.19	4.56	3.24
Construction In Progress	0.25	0.03	-	0.14	-	-
Leasehold Improvements	0.31	0.31	0.63	0.35	0.35	0.35

Source: S&P Capital IQ. Standard template. Financial Sources.